Jun 25, 2019

Video proceedings from the sixth in a series of 6 integrated symposia held at the 2019 ONS Annual Congress. Featuring perspectives from Ms Kelly EH Goodwin, Dr Joel W Neal, Ms Judy Pagtama and Dr Anne S Tsao:

• Introduction (00:00)
  • Program overview: Dr Love
• EGFR-Mutated Metastatic Non-Small Cell Lung Cancer (NSCLC) (9:42)
• Case (Ms Pagtama): A man in his late 50s with Stage IV adenocarcinoma of the lung with an EGFR tumor mutation, a right pleural effusion and a single brain metastasis who received first-line osimertinib (28:51)
• Case (Ms Goodwin): A woman in her early 70s with Stage IV adenosquamous NSCLC with an EGFR tumor mutation who was found to have a MET amplification after disease progression on osimertinib (33:57)
• Immune Checkpoint Inhibitor Therapy for Metastatic NSCLC (41:29)
• Case (Ms Pagtama): A man in his mid-90s with Stage IV pan-wild-type adenocarcinoma of the lung and a high PD-L1 tumor proportion score who received pembrolizumab monotherapy (50:24)
• Case (Ms Goodwin): A man in his mid-60s with extensive metastatic adenocarcinoma of the lung who received carboplatin/pemetrexed/pembrolizumab (1:06:52)
• Immunotherapy as Consolidation After Chemoradiation Therapy for Locally Advanced NSCLC (1:15:58)
• Case (Ms Pagtama): A man in his early 70s with locally recurrent adenocarcinoma of the lung who received concurrent chemoradiation therapy followed by consolidation durvalumab (1:16:26)

Select publications